Haemostatix Ltd.
This article was originally published in Start Up
Executive Summary
Haemostatix Ltd. is a University of Leicester spin-out attempting to develop a synthetic platelet product to aid in blood clotting. The firm was started up in March 2003 and has raised 250,000 GBP from the Lachesis University Challenge Fund.
You may also be interested in...
Artificial Blood: Finding the Formula for Approval
Despite decades of effort and more than $1 billion dollars invested in commercial blood substitute R&D, no products are approved for use in the US. Can next-generation companies succeed where so many others have failed?
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.